Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design.
O'Reilly, M., Cleasby, A., Davies, T.G., Hall, R.J., Ludlow, R.F., Murray, C.W., Tisi, D., Jhoti, H.(2019) Drug Discov Today 24: 1081-1086
- PubMed: 30878562 
- DOI: https://doi.org/10.1016/j.drudis.2019.03.009
- Primary Citation of Related Structures:  
6Q7K, 6Q7S, 6Q7T, 6QA1, 6QA3, 6QA4, 6QAG, 6QAH, 6QAL, 6QAQ, 6QAW - PubMed Abstract: 
We present a novel crystallographic screening methodology (MiniFrags) that employs high-concentration aqueous soaks with a chemically diverse and ultra-low-molecular-weight library (heavy atom count 5-7) to identify ligand-binding hot and warm spots on proteins. We propose that MiniFrag screening represents a highly effective method for guiding optimisation of fragment-derived lead compounds or chemical tools and that the high screening hit rates reflect enhanced sampling of chemical space.
Organizational Affiliation: 
Astex Pharmaceuticals,436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK.